Trials / No Longer Available
No Longer AvailableNCT03874455
Tazemetostat Expanded Access Program for Adults With Solid Tumors
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Epizyme, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Patients with a diagnosis listed under "conditions" below are eligible to be considered for the EAP. These conditions must be serious or life-threatening at the time of enrollment and appropriate, comparable, or satisfactory alternative treatments must have been tried without clinical success. Patients with conditions not listed under "conditions" below are not eligible for the tazemetostat EAP.
Conditions
- Epithelioid Sarcoma (Ex-US Only)
- Spindle Cell Sarcoma
- Sinonasal Carcinoma
- Small Cell Carcinoma of the Ovary Hypercalcemic Type
- Thoracic Sarcoma
- Poorly Differentiated Chordoma
- ATRT
- Malignant Rhabdoid Tumor of Kidney
- Malignant Rhabdoid Tumor of Ovary
- Malignant Rhabdoid Tumor
- Myxoid Spindle Cell Sarcoma
- Epithelioid Malignant Peripheral Nerve Sheath Tumor
- Chondrosarcoma
- Renal Cell Carcinoma
- Myoepithelial Carcinoma
- Synovial Sarcoma
- Renal Medullary Carcinoma
- Malignant Mesothelioma
- Desmoplastic Small Round Cell Tumor (DSRCT)
- Intramedullary Spinal Cord Schwannomatosis
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tazemetostat | Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene |
Timeline
- First posted
- 2019-03-14
- Last updated
- 2024-03-22
Source: ClinicalTrials.gov record NCT03874455. Inclusion in this directory is not an endorsement.